INMD - InMode rises 5% on Q3 result beat

• InMode ( NASDAQ: INMD ) is trading 5% higher after the company posted better-than-expected result and forecast 2022 revenue, profit above estimates, helped by increase in its minimally invasive and subdermal ablative treatments.
• Q3 Non-GAAP EPS of $0.66 beats by $0.08, while Revenue rose 28.7% Y/Y to $121.2M, and beat estimates by $5.11M.
• The company forecast 2022 revenue between $445M and $450M vs. consensus of $440.82M and Non-GAAP earnings per diluted share between $2.28 and $2.30 vs. consensus of $2.22.
• Non-GAAP earnings per diluted share between $2.28 and $2.30 vs. consensus of $2.22.
• "Sales of disposables continued to grow year over year and contributed more to the revenue mix, as our platforms are being used more frequently by our customers," the company said.

For further details see: